Table 2 Laboratory features in severe vs. non-severe hospitalized patients with COVID-19
Outcomes | Severe groups vs. non-severe groups | ||
|---|---|---|---|
No | Pooled WMD (95% CI) | Heterogeneity (I2%, Pa) | |
Lymphocyte | 22 | − 0.43 (− 0.56, − 0.30) | 90.1%, 0.000 |
Monocyte | 10 | − 0.06 (− 0.12, − 0.01) | 71.8%, 0.000 |
Eosinophil | 5 | − 0.03 (− 0.05, − 0.00) | 86.1%, 0.000 |
Hb | 9 | − 5.94 (− 8.23, − 3.64) | 0.0%, 0.952 |
Platelet | 17 | − 27.97 (− 39.6, − 16.35) | 55.8%, 0.003 |
Neutrophil | 18 | 0.74 (0.16, 1.33) | 74.6%, 0.000 |
WBC | 21 | 0.55 (− 0.09, 1.19) | 81.3%, 0.000 |
Albumin | 12 | − 4.20 (− 5.99, − 2.41) | 73.9%, 0.000 |
ALT | 15 | 6.65 (4.21, 9.09) | 0.0%, 0.492 |
AST | 14 | 11.91 (8.29, 15.53) | 46.1%, 0.030 |
TBIL | 9 | 0.08 (0.03, 0.14) | 0.0%, 0.953 |
BUN | 9 | 2.34 (0.66, 4.03) | 39.3%, 0.106 |
Cr | 14 | 0.08 (0.03, 0.12) | 0.0%, 0.930 |
Creatine kinase | 14 | − 3.01 (− 12.91, 6.90) | 51.7%, 0.013 |
Troponin I | 5 | 0.27 (− 0.14, 0.67) | 77.3%, 0.001 |
Myoglobin | 3 | 8.11 (− 6.10, 22.33) | 73.2%, 0.024 |
ESR | 9 | 27.67 (22.94, 32.40) | 22.3%, 0.245 |
CRP | 18 | 36.61 (24.40, 48.82) | 91.9%, 0.000 |
Lactate dehydrogenase | 11 | 102.15 (72.76, 131.53) | 50.3%, 0.028 |
Procalcitonin | 12 | 0.03 (0.00, 0.06) | 41.1%, 0.067 |
IL-6 | 6 | 0.54 (− 0.37, 1.45) | 95.5%, 0.000 |
Sodium | 9 | − 1.95 (− 2.87, − 1.03) | 75.5%, 0.000 |
Potassium | 9 | − 0.07 (− 0.18, 0.04) | 34.3%, 0.144 |
Fibrinogen | 4 | 0.8 (0.32, 1.28) | 82.2%, 0.001 |
Protrombine | 8 | 0.63 (0.27, 0.99) | 69.2%, 0.002 |
D-dimer | 12 | 0.18 (0.10, 0.27) | 99.3%, 0.000 |
Glucose level | 4 | 12.43 (1.95, 22.91) | 0.0%, 0.433 |
Neutrophil‐to‐Lymphocyte ratio | 18 | 0.23 (0.08, 0.37) | 14.6%, 0.279 |
Lymphocyte-to-C-reactive protein ratio | 18 | − 8.12 (− 10.05, − 6.18) | 98.6%, 0.000 |
Leukocyte-to-C-reactive protein ratio | 17 | − 1.47 (− 2.13, − 0.80) | 94.6%, 0.000 |
Leukocyte-to-IL-6 ratio | 5 | − 0.99 (− 1.98, − 0.00) | 93.6%, 0.000 |